MARKSANS PHARMA is in Wave 3 after Multi-Year Breakout!!Analysis Date: June 24, 2024
Marksans Pharma Stock Analysis:
General Trend:
The stock was in range for years, the previous monthly high for Marksans Pharma was Rs. 115 in August 2015. According to Elliott Wave theory, this marked the completion of Wave 1, followed by a correction and completion of Wave 2 on March 2020 and entered Wave 3.
A breakout above the previous monthly high of Rs. 115.10 was recorded in July 2023. In August, September, and October 2023, the price retested the previous high and broke out again in November, accompanied by good volume.
Entry and Exit Points:
As per ichimoku the stock still in bull mode in monthly time frame and good accumulation last few months between 140-180.
Long-term Perspective: The accumulation price range is a good area to buy the stock, with a stop loss set at Rs. 110 (monthly candle close not spike).
Short-term Perspective: Fresh buyers can enter at CMP 162 and keep averaging till near the bottom of the accumulation zone and exit near the high of the range or hold or for two supply zones till 270. The stop loss will be1 hour candle close below RS. 135.
Expected Target:
Marksans Pharma is expected to hit supply zone 1 and 2 marked in the chart, once it breaks out of the accumulation zone. This target is derived based on the application of Fibonacci extension.
Disclaimer: We are not SEBI registered. The content presented here is based on our personal opinions. Conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Pharmastocks
Daily Bullish Flag Breakout in Pharma stockA Bullish Breakout of Flag and Pole pattern is visible on the Weekly chart of NSE:POLYMED
MACD already gave Positive crossover on Daily and Monthly chart. So, expecting the momentum to continue.
One can create a fresh position in the scrip as per the levels mentioned on the chart.
HIT THE ROCKET BUTTON IF YOU LIKE TO BOOST THE IDEA.
Risk Disclaimer:
The information provided in this analysis is based on my personal interpretation of market conditions and the available data at the time of writing. It is advisable to seek advice from a qualified financial professional and to conduct your own research before making any investment decisions.
Syngene-A pre breakout trade for good returns!Sygene is a pharma stock which is consolidating from few months now.
Stock has formed triple bottom pattern near its strong support and now showing signs of reversal
Confirmation is when stock gives weekly closing above 750.
Risky traders can keep this stock in watchlist
Supriya Lifeciences Episodic Pivot TradeSupriya Lifesciences made a gap up (episodic pivot) on 8th Feb due to its blockbuster earnings, intresting part is even in the carnage of Smallcap & Midcaps the gap has been sustained continuously for 3 consecutive days, and never did it break the low of the EP candle. This shows strength in the scrip and I believe in the coming days once the market recovers, this scrip will move easily towards 400, 440 zone.
Stoploss 312
DISCLAIMER*
This analysis is only for educational purpose. I am not a SEBI Registered Analyst/Advisor. Please consult your financial advisor before taking any position and please use a Stop Loss for any Investments/Trading Positions. It is your hard earned money so give risk management your highest attention. Do take this disclaimer seriously.
DIVIS LAB: H&S ContinuationFrom Mar'23 bottom of 2730 stock has rallied and made a high of 3934 in Aug'23. Post that stock has undergone into a correction which already concluded at Nov'23 bottom of 3295. From there stock has rallied again and broken it's previous swing high made in Aug'23. The recent price action suggests that stock has formed a Continuation H&S and given a breakout on 26th dec'23 and trading well above it's neckline. The measured target for this pattern is coming in the region of 4370-4400 zone.
NGL Fine Chem Ltd | a Momentum pharma stockNGL Fine Chem Ltd | a Momentum pharma stock
Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products.
Financial:
Market Cap = 1,382 Cr. ROCE = 11.5 % ROE = 9.31 %
Debt to equity = 0.11 Promoter holding = 73.1 % Piotroski score = 4.00
Quick ratio = 2.06 Current ratio = 2.58 Return on assets = 7.11 %
Profit Var 3Yrs = 18.5 % Sales growth 3Years = 21.8 % Pledged percentage = 0.00 %
in Technically you can see monthly and weekly strong RSI Momentum
financially also debt free company as well as company has good capex plan in comming years
so this will be next multibagger if hold for long time.
Note: I am not SEBI registered financial Adviser. I solely present my views on chart .I do not charge any kind of service. This is not buy sell recommendation.
If you like my ideas than like ,boost and follow me for more ideas.
Thanks and comment freely
GSK Pharma- Ready to breakout?As explained, Glaxo is looking strong for a reversal near support trendline. Trendline breakout can be a beartrap.
RSI positive divergence in weekly TF is supporting the analysis. Best buy is near 1265 with SL below 1227 and target of 1345+.
However, this idea is shared just for educational purposes and not a recommendation.
Sequent Scientific PE is negative at -42
THE CARLYLE GROUP ACQUIRES A MAJORITY STAKE IN SEQUENT SCIENTIFIC LIMITED
Shares of Sequent Scientific soared over 9 percent in early trade on September 15 after the company's board approved the sale of its API (Active Pharmaceutical Ingredient) facility in Thane
Sequent Scientific (NSE:SEQUENT) delivers shareholders decent 8.8% CAGR over 5 years
Sequent Scientific shares jump 15% after terminating Tineta Pharma's proposed acquisition
mutual funds have increased stake from 0.25% to 1%
DII also increasing stake significantly
stock has come out of accumulation Phase!!!
Long TRADE in LUPIN PHARMA Any who wants to add a quality stock in their demat can be go with LUPIN because lupin pharma share has been in very good strong upward momentum from the last 6 months and higher chances of that it will continue its upward journey .Because of the pattern of the share is like first go up and then go down , then again go up and then some downwoard moves , from last almost 1to2 months this process can be shown in charts also , and you can also see very well , so anyone who wants to outshine their portfolio can add this at their own risk management , at now level lupin share has favourable risk reward ratio , in all my ideas published in the trading view has a almost target of the 3 to 4 percent , after 3 to 4 percent target achieved my target is done.3to4 percent counts on current price which is shown in chart as well , so from my side this is good bet previously i shared ANANT RAJ in which almost 3 percent target is DONE AND DUSTED , and IMPORTANT NOTICE:-In my observation and analysis this share has can move without any market support , this share has countinuesly outperform market when our market are flat or consolidating between the area .WAITING TIME is almost 10 to 15 days holding period and , stop loss is nearly 1.5 percent of the current share price as shown in the charts ,, so anyone who can love pharma sector can go with this share with their risk capacity. in my observation this share can start upward journey soon , and yes this share can go up slow as seev in previous chart so dont go for very quick or fast move , this share headed upward slowly slowly . in my experience when a small fall occurs this share fill the fall within 5to6 days like slow and steady , so thanks for reading my long message if you read my message till now than you are amazing person and have a very serious mind in trading , because most of the people don't read this large message ha ha ha ha ha
DISCLAIMER:-I have already invested in this share , and all profit and loss in this share is BSE:LUPIN yours , my work is to share idea of the good company in which you will make a good return, and if you earn profit from this share so please feel free to comment in the comment section ,